Acorda Therapeutics (ACOR) 26.31 $ACOR Anavex's Lead

New Post Public Reply Private Reply Replies (0) Message Board

Jun 24, 2016 at 4:12 AM

Acorda Therapeutics (ACOR) 26.31 $ACOR

Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 4.27 (+0.12), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Fate's (FATE) ProTmune Gets Fast Track Status, Stock Up
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 10:46AM CDT
Fate Therapeutics (FATE) announced that the FDA has granted the Fast Track status to its immunotherapy ProTmune.
FATE: 1.83 (unch), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

7 Biotech Stocks that are Buys Right Now
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 10:00AM CDT
Buy these seven biotech stocks now and see how well the second half of 2016 unfolds for this industry.
MSTX: 0.46 (+0.01), RTRX: 18.49 (+0.01), AVEO: 0.98 (-0.01), SNSS: 0.55 (-0.01), LGND: 115.11 (+1.28), BIND: 0.40 (-0.01), ACOR: 26.31 (+1.04)

Biotie Therapies Corp. Announces That the Delisting of Its American Depositary Shares from NASDAQ Global Select Market Has Become Effective
BusinessWire - Mon Jun 13, 8:30AM CDT
Biotie Therapies Corp. (Nasdaq Helsinki: BTH1V) ("Biotie" or the "Company"

announces that the voluntary delisting of its American Depositary Shares ("ADSs"

from the NASDAQ Global Select Market ("Nasdaq US"

became effective prior to the opening of trading on 13 June, 2016, following the filing, on 2 June 2016, of an application on Form 25 with the U.S. Securities and Exchange Commission (the "SEC"

for notifying the SEC of the delisting of the Company's ADSs from NASDAQ US, as announced on 18 May 2016.
BITI: 25.80 (-0.71), ACOR: 26.31 (+1.04)

The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 8:30AM CDT
The Zacks Analyst Blog Highlights: Biogen, Merrimack Pharmaceuticals, Retrophin, Idera Pharmaceuticals and Acorda Therapeutics
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Pre-market Insights on Biotechnology Stocks -- BioMarin Pharma, Alexion Pharma, Aegerion Pharma, and Acorda Therapeutics
PR Newswire - Thu Jun 09, 7:40AM CDT
On Wednesday, June 08, 2016, the NASDAQ Composite ended the trading session at 4,974.64, up 0.26%; the Dow Jones Industrial Average advanced 0.37% to finish at 18,005.05; and the S&P 500 closed at 2,119.12, up 0.33%. The gains were broad based as all the sectors ended the session in positive. ActiveWallSt.com has initiated coverage on the following equities: BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Alexion Pharmaceuticals Inc. (NASDAQ: ALXN), Aegerion Pharmaceuticals Inc. (NASDAQ: AEGR), and Acorda Therapeutics Inc. (NASDAQ: ACOR). Learn more about these stocks by accessing their free trade alerts at:
BMRN: 83.65 (+1.47), ALXN: 123.57 (+2.16), AEGR: 1.67 (+0.11), ACOR: 26.31 (+1.04)

Acorda Presents Phase 1 Data on CVT-427 for Acute Treatment of Migraine at 58th Annual Scientific Meeting of the American Headache Society
BusinessWire - Thu Jun 09, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced pharmacokinetic (PK) data from a Phase 1 study of CVT-427, an inhaled formulation of zolmitriptan, resulting in increased bioavailability and faster absorption compared to oral and nasal administration of the same active ingredient in healthy adults. The data on CVT-427, an investigational agent under development for the acute treatment of migraines, will be presented on June 10th, 2016, at the 58th Annual Scientific Meeting of the American Headache Society, in San Diego, CA.
ACOR: 26.31 (+1.04)

Forget Biogen (BIIB), Buy These 5 Biotech Stocks Instead
Arpita Dutt - Zacks Investment Research - Wed Jun 08, 9:52AM CDT
Lack of near-term pipeline catalysts, the MS franchise's performance, Tecfidera patent challenges and pipeline setbacks are some of the factors that are currently impacting Biogen (BIIB).
MACK: 6.12 (-0.08), BIIB: 238.62 (+4.02), IDRA: 1.53 (+0.05), RTRX: 18.49 (+0.01), LGND: 115.11 (+1.28), ACOR: 26.31 (+1.04)

Celldex (CLDX) Presents Phase II Melanoma Study Data
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 9:45AM CDT
Celldex Therapeutics (CLDX) announced positive phase II data evaluating CDX-301 and CDX-1401 in patients with malignant melanoma at ASCO.
ANIP: 56.27 (+3.48), CLDX: 4.57 (+0.12), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Acorda Therapeutics to Present at the 37th Annual Goldman Sachs Global Healthcare Conference
BusinessWire - Tue May 31, 6:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Michael Rogers, Chief Financial Officer, will present at the Goldman Sachs Global Healthcare Conference on Tuesday, June 7 at 2:00pm PT (5:00pm ET).
ACOR: 26.31 (+1.04)

The Medicines Co. Carbavance TANGO 1 Study Enrolled
Zacks Equity Research - Zacks Investment Research - Fri May 27, 1:45PM CDT
The Medicines Company (MDCO) announced that it has completed enrollment in the phase III TANGO 1 study on Carbavance for the treatment of cUTI.
MDCO: 34.54 (+1.31), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Alkermes Begins Phase I Study on Immuno-Oncology Drug
Zacks Equity Research - Zacks Investment Research - Thu May 26, 10:30AM CDT
Alkermes (ALKS) announced the initiation of a phase I study on its immuno-oncology candidate ALKS 4230 for the treatment of solid tumors
ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04), ALKS: 43.75 (+0.71)

Biotech Stock Roundup: XenoPort Soars on Acquisition Deal, AbbVie Crohn's Disease Drug Fares Well
Arpita Dutt - Zacks Investment Research - Wed May 25, 2:02PM CDT
Deals and acquisitions were in focus this week in the biotech sector while AbbVie's (ABBV) recently in-licensed candidate fared well in a mid-stage study.
VRTX: 88.20 (+2.98), HZNP: 17.44 (+0.66), ICPT: 154.26 (+6.16), ABBV: 61.31 (+0.92), ACOR: 26.31 (+1.04), BIOD: 0.31 (-0.02), XNPT: 7.03 (+0.02)

Acorda Shelves Development of Epilepsy Treatment, Plumiaz
Arpita Dutt - Zacks Investment Research - Mon May 23, 6:39AM CDT
Acorda's (ACOR) decision to terminate the development of Plumiaz was based on data from ongoing studies.
HSKA: 34.55 (+0.65), ANIP: 56.27 (+3.48), RTRX: 18.49 (+0.01), ACOR: 26.31 (+1.04)

Acorda to Discontinue Development of PLUMIAZ for Treatment of Epilepsy Seizure Clusters
BusinessWire - Fri May 20, 5:00AM CDT
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that it will discontinue development of PLUMIAZ(TM) (diazepam) Nasal Spray, an investigational therapy being studied for the treatment of seizure clusters in people with epilepsy. Data from the ongoing clinical trials do not demonstrate its bioequivalence to Diastat(R) rectal gel, needed to re-file the New Drug Application (NDA) under section 505(b)(2). Specifically, the data demonstrated unexpectedly lower nasal mucosa absorption of diazepam in persons with epilepsy compared to studies in healthy volunteers.
ACOR: 26.31 (+1.04)

Biotie Therapies Corp. to Delist Its American Depositary Shares from the Nasdaq Global Select Market
BusinessWire - Wed May 18, 8:00AM CDT
Biotie Therapies Corp. ("Biotie"

today announces that its Board of Directors has resolved to voluntarily delist its American Depositary Shares ("ADSs"

, each representing 80 Biotie ordinary shares with no nominal value ("Shares"

, from the NASDAQ Global Select Market ("NASDAQ US"

.
ACOR: 26.31 (+1.04)

BIOTIE CANCELS ALL TREASURY SHARES HELD BY THE COMPANY
Globe Newswire - Wed May 18, 1:02AM CDT
BIOTIE THERAPIES CORP. STOCK EXCHANGE RELEASE 18 May 2016, at 9.00 a.m. (EET)
BITI: 25.80 (-0.71), ACOR: 26.31 (+1.04)

Dry Powder Inhaler Devices Medical Devices Pipeline Assessment, 2016 - Analysis, Technologies & Forecasts Report - Key Vendors: Acorda Therapeutics, Bespak Europe, Nekta - Research and Markets
BusinessWire - Fri May 13, 9:31AM CDT
Research and Markets has announced the addition of the "Dry Powder Inhaler Devices - Medical Devices Pipeline Assessment, 2016" drug pipelines to their offering.
ACOR: 26.31 (+1.04)

Aegerion Enters into Settlement Agreement with DoJ and SEC
Zacks Equity Research - Zacks Investment Research - Fri May 13, 8:36AM CDT
Aegerion Pharmaceuticals, Inc. (AEGR) announced that it has reached preliminary agreements with the U.S. DoJ and staff of the SEC.
ABT: 39.63 (+0.89), AEGR: 1.67 (+0.11), ACOR: 26.31 (+1.04), SNY: 41.19 (+0.90)

Drug Stocks Q1 Earnings Slated on May 11: ACRS, EARS & More
Zacks Equity Research - Zacks Investment Research - Tue May 10, 8:45AM CDT
With the Q1 cycle nearing its end, the earnings picture is becoming increasingly clear. While the going looked tough at the onset of the last month, that scenario has changed over the past few weeks.
CRME: 5.00 (+0.05), JNJ: 117.38 (+0.92), EARS: 4.00 (-0.05), GILD: 83.37 (+0.92), BITI: 25.80 (-0.71), BPTH: 2.18 (+0.04), AMGN: 152.27 (+2.46), ACRS: 18.21 (+0.14), ACOR: 26.31 (+1.04), NVS: 80.67 (+0.96)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NOWINCLUDED Unfiltered: Podcasting's New Trailblazer

Signals of Change in Podcasting In a world of constant noise, finding a voice that cuts through the chatter is a rarity. Enter NOWINCLUDED Unfiltered, the podcast hosted by Tiffany Whitlow that's making waves for its unique approach to tackling some of healthcare's most pressing issues. This isn't your run-of-the-mill podcast. It's a no-holds-barred dive into health...

Epic Oceanside Estate Set for No-Reserve Luxury Auction

Going, Going, Gone? A Golf Exec's Dream Home What's hotter than Florida's summer sun? It's this swanky estate at Ponte Vedra Beach set to hit the auction block without any safety net. Yup, no reserve, folks! Leonard "Len" Brown, Jr., the brains behind many of PGA Tour's global ventures, has decided to put his lavish 3.2-acre plot right by the ocean up for grabs. Once...

Utopia Bagels Honored at 2026 New York BagelFest

From Queens Streets to Global Fame Try to picture this: a small neighborhood shop where the scent of freshly baked bagels wafts through, bringing together old friends and new generations. Now, take that local magic and multiply it by a global stage. That's the journey Utopia Bagels from Queens stepped into with massive strides over 45 years, earning a celebrated spot in...

Gentex Faces Investigation as Shares Tumble 7%

Investigating Gentex's Financial Setback Gentex Corporation, ticker NASDAQ:GNTX, is caught in a bit of a blizzard right now. Their shares took a nosedive, down 7%, after some messy numbers came out in their third-quarter report—tariffs and the kind of pricing pressure that makes grown investors wince. If you threw your chips in on Gentex and got burned, the lawyers are...

New PGCE Aims to Boost Confidence in Private Tutoring

Shifting the Landscape of Private Tutoring Here's a turn of events: parents now have a new tool at their disposal to vet private tutors. The recently unveiled PGCE Tutoring by UWE Bristol aims to provide an added layer of confidence for families navigating the private tutoring market. Breaking the Myth of Tutor Qualifications Did you know a whopping 54% of UK adults think...

OperaWine 2027 Spotlights Women-Led Italian Wineries

The Rise of Women's Leadership in Italian Winemaking If there’s anything that gets me up off the bench, it’s innovation in tradition. And that's just what Vinitaly OperaWine is doing in 2027. For the first time, they've carved out a special category, "Led by Women," featuring a lineup of 46 Italian wineries ran by women. These ladies are stepping into the limelight at...

Breaking Down Oklahoma's Car Insurance Costs

Understanding Car Insurance Dynamics in Oklahoma In the labyrinth of car insurance premiums, drivers in Oklahoma are left navigating a multitude of factors. A recent article from HelloNation, featuring insurance agent Bobby Williamson, dives into these elements with a candor that cuts through the fluff. Understanding what drives those numbers up or down isn't just for the...

Govee's Retro Holiday Lights: A Festive Nostalgia Trip

Ah, the holidays—they're creeping up like a kid sneaking downstairs for a peek at their gifts. But it's not the gifts under the tree that brighten a room, it's those lights draping the tree itself. Enter Govee, bringing us back to that vintage glow we all remember from our childhoods. They've teamed up with Brady Tolbert, a design whiz who can make a living room look...

Sands China's Latest Move: A Bond Offering Twist

Breaking Down Sands China's Bond Maneuver Today, we found out that Sands China is teeing up a fresh round of senior unsecured notes. Now, if that doesn't get your ticker flickin', maybe you're too used to market snoozefests. The folks at the helm of Sands China, a subsidiary under the mighty Las Vegas Sands Corp. (NYSE: LVS), are rolling out these USD-denominated notes...

PG&E Halts Service; Groups Demand Regulatory Action

Pending Storm Over PG&E's Service Delays It's rare that you hear a utility company flat-out say it can't afford to keep the lights on. Yet here we are, staring down the barrel of some unsettling news for 25,000 PG&E customers. They've been warned they might cool their heels for an extra six months before their service is up and running. As if that's not dicey enough, $2...